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Kaposi’s sarcoma (KS) is a complex proliferative lesion long suspected of being dependent on exogenous paracrine
signaling molecules to stimulate its proliferative, angiogenic, and inflammatory components. In particular, both clinical and
experimental observations have pointed to a potential role for inflammatory cytokines as permissive factors for KS
development, but KS pathogenesis is also critically dependent on infection by an exogenous herpesvirus, the KS-associated
herpesvirus (KSHV). To examine the possible links between inflammatory cytokines and KSHV replication, we tested for the
ability of such cytokines to induce lytic viral reactivation in the latently infected BCBL-1 cell line. Interferon-g consistently
activated KSHV replication, whereas tumor necrosis factor, interleukin-1, interleukin-2, interleukin-6, granulocyte-macrophage
colony stimulating factor, and basic fibroblast growth factor did not. Glucocorticoids also failed to induce lytic KSHV growth
in these cells, but ionomycin, a calcium ionophore, induced replication and strongly augmented the known inductive effects
of phorbol esters. Interferon-a had a dose-dependent inhibitory effect on KSHV induction by ionomycin. The identification of
interferon-g as an activator and interferon-a as an inhibitor of KSHV induction in vitro correlates well with in vivo observations
and demonstrates for the first time that inflammatory cytokines can directly modulate KSHV replication. © 2000 Academic PressINTRODUCTION
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV),
also called human herpesvirus 8 (HHV8), is a novel
human gammaherpesvirus that is tightly linked to KS and
several other human diseases. KSHV sequences have
been found in virtually all KS lesions tested, and several
lines of epidemiological evidence suggest that KSHV is
necessary for KS pathogenesis (reviewed in Boshoff and
Weiss, 1997; Ganem, 1997; Schulz et al., 1998). Infection
with KSHV precedes clinical KS, and antecedent KSHV
seropositivity strongly predicts increased KS risk (Martin
et al., 1998; Renwick et al., 1998; Whitby et al., 1995).
Globally, the seroprevalence of KSHV in different regions
is tightly correlated with the prevalence of the tumor
(Gao et al., 1996; Kedes et al., 1996; Mayama et al., 1998;
Simpson et al., 1996; Whitby et al., 1998). At the cellular
level, viral DNA and RNA sequences are present in the
majority of the spindle-shaped endothelial cells thought
to be the prime movers of KS histogenesis (Boshoff et al.,
1995; Staskus et al., 1997). Most such cells are latently
infected, but a small subpopulation also supports lytic
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1viral growth (Staskus et al., 1997). KSHV infection is also
found in infiltrating monocytes in KS tumors (Blasig et al.,
1997) and in the B cell compartment of peripheral blood
mononuclear cells (Ambroziak et al., 1995).
Because KSHV is a lymphotropic herpesvirus whose
natural target is the B cell (Ambroziak et al., 1995; Mesri
et al., 1996), lytic reactivation from its lymphoid reservoir
would appear to be required for spread to the endothe-
lium during the early stages of KS pathogenesis. In
addition, because several lytic gene products of the virus
can stimulate angiogenesis (Bais et al., 1998; Boshoff et
al., 1997), it is possible that lytic replication in the target
endothelium can also directly contribute to this aspect of
KS lesions. Thus factors associated with enhanced lytic
KSHV growth can plausibly be envisioned to increase KS
risk. The known linkage of KS with immune deficiency
may operate, at least in part, on this basis: by immuno-
deficiency, leading to a failure to control KSHV replication
and spread.
Clinical and experimental observations suggest that
many paracrine factors are also likely to be involved in
KS pathogenesis. The dramatic acceleration of KS some-
times observed after severe bouts of sepsis (Krown,
1999) or after glucocorticoid administration (Perez et al.,
1998; Trattner et al., 1993) has suggested that modulators
of inflammation may play an important permissive role in
KS development. In the mid-1980s, attempts to treat KS
with certain immunomodulatory cytokines produced
mixed results; although interferon-a (IFN-a) was mod-
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18 CHANG ET AL.estly beneficial (Evans et al., 1991; reviewed in Krown,
1998; Krown et al., 1983), treatment trials with tumor
necrosis factor (TNF) and interferon-g (IFN-g) were aban-
doned because of several episodes of dramatic worsen-
ing of the tumor (Aboulafia et al., 1989; Ganser et al.,
1986; Krigel et al., 1985). Beyond these clinical observa-
tions, extensive laboratory experiments have also sug-
gested a role for cytokines and growth factors in KS
biology. KS lesions display elevated levels of mRNA for
many cytokines, including basic fibroblast growth factor
(bFGF), interleukin 1 (IL-1), platelet-derived growth factor,
IL-6, TNF, and IFN-g (reviewed in Ensoli and Sturzl, 1998;
Fiorelli et al., 1998; Oxholm et al., 1989; Sturzl et al., 1995;
Xerri et al., 1991), and cultured KS spindle cells express
a wide variety of cytokines and growth factors, including
IL-1, IL-6, IL-8, vascular endothelial growth factor, and
bFGF (Ensoli et al., 1989; Miles et al., 1990; Samaniego et
al., 1998; Sciacca et al., 1994). The growth of KS spindle
cells in vitro generally requires conditioned media from
activated lymphocytes or PBMCs (Nakamura et al., 1988);
such media typically contain high concentrations of TNF,
IFN-g, IL-1, IL-6, and oncostatin M (Barillari et al., 1992;
air et al., 1992; Samaniego et al., 1995). Recently, Siri-
nni et al. (1998) reported increased cytokine (IFN-g)
production in PBMCs and tumor-infiltrating lymphocytes
derived from KS patients. Based on these and other
findings, it has been postulated that KS pathogenesis
may be critically dependent on the presence of appro-
priate inflammatory signals emanating from the tumor’s
microenvironment.
What has remained unclear is how the viral and cyto-
kine components of the pathogenesis of KS are related.
To shed light on this question, we examined the ability of
a large panel of cytokines and growth factors to modu-
late the lytic reactivation of KSHV from latency. Our re-
sults indicate that at least one inflammatory cytokine,
IFN-g, can induce KSHV replication from its latent state
n B cells, providing one plausible mechanism that di-
ectly links these two distinctive contributors to KS risk.
onsistent with such a linkage, IFN-a, a compound
known to ameliorate KS lesions, has the ability to blunt
KSHV growth.
RESULTS
A quantitative assay system for lytic reactivation
The BCBL-1 cell line is a B cell line derived from a
KSHV-related primary effusion lymphoma. In the ground
state, the cells are latently infected with KSHV but can be
induced to undergo lytic viral replication on treatment
with a variety of chemical inducers, such as the phorbol
ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (Renne
t al., 1996a,b). Our previous studies of lytic reactivation
nvolved the assay of lytic viral mRNAs or DNA in mass
ultures of BCBL-1 cells (Renne et al., 1996b). Although
efinitive, these assays do not allow assessment of sub-le alterations in reactivation levels; as such, although
hey work well for powerful artificial inducers like TPA,
hey cannot detect the lower levels of induction likely to
e produced by physiologically relevant compounds.
his is because BCBL-1 cells have a measurable back-
round level of spontaneous reactivation (Renne et al.,
996b); twofold to fourfold induction above this level
ould be difficult to credibly detect in a mass culture, as
ould higher levels of induction in small subpopulations
f cells, but either of such scenarios could be highly
hysiologically relevant. To test a variety of different
hemical and biological compounds for their ability to
eactivate BCBL-1 cells, we used an immunofluores-
ence-based assay (IFA) that allows examination of re-
ctivation at the single cell level.
The assay uses a monoclonal antibody (MAb) that
pecifically recognizes the viral K8.1 protein, an envelope
lycoprotein expressed with late kinetics. This protein is
pecific to lytically infected cells; as a late protein, it is
xpressed only in cells that have initiated viral genomic
eplication (Chandran et al., 1998; Raab et al., 1998). Thus
ells staining for this marker are irreversibly committed
o lytic reactivation. To standardize the assay and opti-
ize the time points chosen for examination, we deter-
ined the kinetics of lytic induction using TPA as our
eference standard. About 2.5 3 105 BCBL-1 cells were
plated onto 24-well plates 24 h before induction. At time
zero, 20 ng of TPA was added, and incubation continued
for 1, 3, 5, and 7 days; at those times postinduction,
induced and uninduced cells were harvested by mild
centrifugation for IFA. All IFA assays were performed in
quadruplicate, and the results are expressed as the
percentage of cells scoring positive for K8.1 expression.
In selected instances, reactivity of induced BCBL-1 cells
with K8.1 MAb was also examined by flow cytometry to
allow facile screening of large numbers of cells.
Figure 1 shows data from a typical IFA. Untreated
BCBL-1 have a few cells that score for K8.1 expression,
reflecting the level of spontaneous lytic reactivation in
this cell line (Figs. 1A and 1B). Cells treated with iono-
mycin (Figs. 1C and 1D) and TPA (Figs. 1E and 1F) show
a significant increase in the number of positive cells,
whereas cells treated with both inducers result in even
greater lytic induction (Figs. 1G and 1H). The kinetics of
this induction is shown in Fig. 2. As early as 3 days
postinduction, 4.1% of TPA-treated cells are positive for
K8.1 expression, a 12.5-fold increase over the back-
ground spontaneous rate of activation (0.33%). Ionomy-
cin, a calcium ionophore known to induce EBV from
latency (Faggioni et al., 1986), was also found to be
effective in KSHV induction of BCBL, reaching an induc-
tion ratio of 9.2-fold over background. The combination of
TPA and ionomycin was more potent than either alone,
allowing an induction ratio of 33-fold at 3 days postin-
duction. Similar results are obtained when cells are
scored by flow cytometry for reactivity with K8.1 MAb
c
s
a
z
c
e
g
S
i
m
s exam
19CYTOKINES AND REACTIVATION OF KSHV LYTIC REPLICATION(data not shown). In both systems, there is considerable
day-to-day variation in the percentage of cells induced by
a given inducer. However, within each experiment, the
rank order of inducing stimuli was always constant: TPA
1 ionomycin . TPA . ionomycin. The ability of ionomy-
in to induce KSHV replication indicates an important
timulatory role for intracellular calcium in this process:
potentially important feature, because calcium mobili-
FIG. 1. Lytic reactivation of BCBL-1 by chemical induction. Typical
untreated (A and B) or induced with ionomycin (C and D), TPA (E and
washed, resuspended in PBS, and fixed to 32-well slides for IFA ana
FITC-conjugated goat anti-mouse antibody and visualized by immunoflu
microscopy, and then the corresponding immunofluorescence field wa
Approximately one sixth of a field is shown.ation is one of the hallmarks of the signal transduction
ascade in B cells activated by antigen and other exog-
o
cnous stimuli (DeFranco, 1999), including the viral K1
ene product (Lagunoff et al., 1999; Lee et al., 1998).
creening of inflammatory cytokines for ability to
nduce KSHV
Using the IFA, we screened a large number of inflam-
atory cytokines, singly and in combination, for effects
of BCBL-1 for K8.1 after chemical induction. BCBL-1 cells were left
oth chemical inducers (G and H). At 3 days postinduction, cells were
Positive cells were detected using anti-K8.1 MAb (19B4) followed by
nce microscopy. For each sample, a random field was chosen by light
ined. Total cell count per field ranged from 330 to 1000 cells per field.staining
F), or b
lysis.
orescen the induction of KSHV from latency. Table 1 lists the
ytokines we tested and the results of the screen. IL-2,
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20 CHANG ET AL.IL-6, and granulocyte-macrophage colony stimulating
factor are cytokines regularly found in the conditioned
medium of activated T cells that are often used to sup-
port KS spindle cell cultures (Barillari et al., 1992); IL-6
has previously been suggested to stimulate the prolifer-
ation of such cells (Miles et al., 1990). Although bFGF is
not a mediator of inflammation, its effects were exam-
ined because of its posited role in the stimulation of
KS-like neovascular lesions in mice. We placed particu-
lar emphasis on TNFa and IL-1b, because Ensoli and
oworkers (Nakamura et al., 1988) have shown that
hese cytokines can stimulate spindle cell growth and
an act in concert to stimulate production and release of
FGF from both AIDS-KS-derived spindle cells and nor-
al endothelial cells (Samaniego et al., 1995, 1997).
examethasone was also tested because glucocorticoid
reatment has been known to stimulate the development
f KS lesions. All factors were screened at concentra-
ions previously reported to have effects on KS cells and
cored at 3 days after the addition of the compound. As
hown in Table 1, none of these compounds were active
nducers of KSHV replication. Several combinations of
hese molecules, chosen based on their known pres-
nce in T cell-conditioned medium (Barillari et al., 1992),
were similarly inactive.
Effects of IFNs on KSHV
FIG. 2. Kinetics of induction. BCBL-1 cells were induced with TPA, i
days postinduction and analyzed as above. Data points are the
ndependent experiments are shown.Several considerations led us to explore the effects of
IFNs on KSHV induction. First, the type II, IFN, IFN-g, isone of the predominant cytokines released from T cells
recovered from KS lesions (Sirianni et al., 1998), making
it a prime candidate for a paracrine regulator. Second,
the viral genome encodes for homologs of the cellular
IFN regulatory factor (IRF) family of transcription factors.
Multiple reports have shown that the product of ORF K9,
vIRF-1, can inhibit gene expression induced by type I
IFNs (Gao et al., 1997; Li et al., 1998; Zimring et al., 1998).
This suggests that at least some type I IFNs might be
inhibitory to KSHV growth, providing a selective force for
the evolution of viral strategies for the blunting of such
inhibition. Accordingly we examined both type I and type
II IFNs for their effects on KSHV, using both the manual
IFA and flow cytometric analysis of IFN-treated cells for
K8.1 expression.
Figure 3A shows a flow cytometric analysis of
;30,000 cells exposed to IFN-g and reveals that un-
like the cytokines tested in Table 1, IFN-g is an inducer
of KSHV lytic growth. IFN-g is considerably less active
han the known chemical inducers of reactivation; as
hown in Fig. 3A, it is only about half as active as
onomycin when assayed at day 3 postinduction. Nev-
rtheless, the induction of lytic gene expression by
FN-g could be confirmed by quantitative real-time
T-PCR for lytic mRNAs. Figure 3B shows relative
ranscript levels in treated BCBL-1 cells at day 5
ostinfection. BCBL-1 cells exposed to IFN-g showed
in, or both chemical inducers. Cells were harvested at 0, 1, 3, 5, and
6 SD of quadruplicate inductions. Representative results from twoonomyc10-fold increase in lytic K8.1 and orf50 mRNA levels
compared with untreated cells. As expected, TPA dis-
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21CYTOKINES AND REACTIVATION OF KSHV LYTIC REPLICATIONplayed much stronger induction, with a .100-fold in-
rease in lytic transcript levels. Neither treatment pro-
uced significant enhancement of the latent orf72 (v-
yclin) mRNA (Fig. 3B).
By contrast, treatment of BCBL-1 cells with IFN-a re-
duced the fraction of cells displaying K8.1 expression by
flow cytometry in a dose-dependent fashion (Fig. 4). This
suggests that IFN-a can inhibit spontaneous lytic reac-
tivation. Reactivation induced by ionomycin exposure
was similarly inhibited by IFN-a, again in a dose-depen-
ent way (Fig. 4). IFN-a can also partially inhibit induc-
ion by TPA, although we were never able to observe
omplete inhibition of reactivation by this very potent
rtificial inducer (data not shown). Thus, type I and type II
FNs are able to exert divergent effects on viral reactivation.
DISCUSSION
TABLE 1
Screening of Inflammatory Cytokines and Growth Factors
for KSHV Induction in BCBL-1 Cells
Inducing agent Concentration -Fold induction
o inducing agent 1.0
PA 20 ng/ml 11.7
L-1a 0.1 ng/ml 1.0
1 ng/ml 1.3
10 ng/ml 1.0
L-1b 0.35 ng/ml 1.3
3.5 ng/ml 0.8
35 ng/ml 1.0
L-2 1 ng/ml 0.5
10 ng/ml 0.5
L-6 35 ng/ml 0.8
175 ng/ml 1.0
NF-a 0.1 ng/ml 1.0
1 ng/ml 1.3
10 ng/ml 0.5
M-CSF 0.5 ng/ml 0.8
2.5 ng/ml 0.8
asic FGF 5 ng/ml 1.3
25 ng/ml 0.8
examethasone 1 nM 1.3
10 nM 0.8
100 nM 1.0
L-1a, IL-1b and
TNF-a 1, 3.5, and 1 ng/ml 0.8
10, 35, and 10 ng/ml 1.5
10, 35, and 1 ng/ml 0.5
1, 3.5, and 10 ng/ml 0.5
L-1a, IL-1b, TNF-a,
and GM-CSF 1, 3.5, 1, and 0.5 ng/ml 1.0
Note. BCBL-1 cells were treated with candidate inducing agents at
the concentrations indicated. Cells were harvested at 3 days after-
treatment and quantified as described in the legend to Fig. 1. Data are
presented as -fold induction relative to untreated cells. GM-CSF, gran-
ulocyte-macrophage colony stimulating factor.These data establish that products of host immune
nd inflammatory responses can directly modulate KSHVeplication. These modulatory effects are notable for
heir selectivity; of the large number of cytokines (and
ytokine combinations) tested, only two were active, with
FN-g positively regulating lytic replication, whereas
IFN-a inhibited induction. The failure of most other com-
ounds tested to influence KSHV replication in our in
itro system does not, of course, exclude potential roles
or these compounds in the modulation of viral replica-
ion in vivo. Our experiments uses a PEL (B cell) line, but
SHV also targets endothelial (spindle) cells and mono-
ytes in vivo. Such cells may respond to entirely different
ets of stimuli. In addition, we think it is likely that other
nflammatory mediators will also be found to influence
SHV dynamics in B cells in vivo. For example, because
FN-g is a major cytokine involved in Th1-mediated re-
sponses, factors known to up-regulate IFN-g release
(e.g., IL-18 or IL-12; Dinarello, 1999; Yoshimoto et al.,
1998) or augment Th1 responses more generally might
also be expected to influence viral replication. However,
the effects of Th1 upregulation on KSHV growth in vivo
might be opposed by augmented CTL killing of infected
cells, so the net effects of such Th1 modulation in vivo
cannot be unambiguously predicted from our simple in
vitro experiments.
As expected, the stimulatory effects of IFN-g were
smaller than those induced by artificial chemical stimuli
but were highly reproducible and were achieved using
concentrations of cytokine comparable to levels seen in
sera of patients at late stages of HIV disease (Rossol et
al., 1989). Although our results reflect in vitro assays,
there is good reason to believe that they may be relevant
to KS pathogenesis in vivo. They provide a plausible
mechanistic basis for long-standing clinical observations
linking inflammatory processes to KS progression in vivo.
They are also consistent with the failure of IFN-g in the
therapy of clinical KS and provide at least one potential
explanation for the acceleration of disease progression
observed in early trials of the drug (Ganser et al., 1986;
Krigel et al., 1985). In addition, very recent experiments
show that PBMCs from KSHV-positive patients grown in
culture tend to lose the virus unless IFN-g is present to
aintain and, in some cases, increase viral load (Monini
t al., 1999b). Although such experiments do not differ-
ntiate direct effects of IFN-g on virus-producing cells
rom indirect effects of factors released from uninfected
onocytes or other cells present in these complex pop-
lations, our experiments indicate that the direct effects
f IFN-g may suffice to account for these findings. To-
ether with these data, our results raise the question of
hether down-regulation of IFN-g would be of prophy-
actic or therapeutic benefit in KS.
Our studies with IFN-a also are in accordance with the
known effects of this compound in vitro and in vivo.
Culture of PBMCs from KSHV-infected subjects with high
doses of IFN-a results in a twofold decrease in viral load
(Monini et al., 1999a). Although this result again could
O
i
s
T
O
v
a
c e subtr
re repr
22 CHANG ET AL.reflect the direct or indirect effects of IFN-a, our data
suggest that direct inhibition is the likely mechanism.
IFN-a is also known to be modestly active in the therapy
of KS (Evans et al., 1991; Krown, 1998; Krown et al., 1983).
ur results show that it is a weak inhibitor of KSHV
nduction, with significant inhibition of viral growth ob-
erved principally at high concentrations of the protein.
he weakness of the inhibition may be the result of KSHV
RF K9 expression, which acts to oppose IFN-a-medi-
ated gene expression (Gao et al., 1997; Li et al., 1998;
Zimring et al., 1998) and thus can blunt its antiviral
FIG. 3. (A) IFN-g and ionomycin induction of KSHV. BCBL-1 cells w
postinduction, cells were harvested and quantified by FACS. Data we
untreated cells from the same time point. Error bars represent the SD o
are shown. (B) Total RNA was isolated from 106 cells (mock treated, I
ariability between inductions. RNA from each duplicate was analyzed
mount of RNA in each reaction, GAPDH was coamplified in the same
ycle (Ct) values for KSHV-specific transcripts (orf72, orf50, orfK8.1) wer
-fold over mock treated cells for each treatment group. Mean values aactions. Formal proof of this, however, must await the
development of genetic systems for the isolation andcharacterization of K9 mutant viruses, which would be
predicted to display enhanced sensitivity to type I IFNs.
MATERIALS AND METHODS
Cell culture and KSHV induction
The BCBL-1 cell line was propagated and maintained
as described previously (Renne et al., 1996b). Cells were
split to a density of 2.5 3 105/ml at 12–20 h before
induction. On day 0, cells were washed once with PBS
and then resuspended to the original volume with fresh
duced with IFN-g (30 U/ml) or ionomycin (500 nM). At 1 and 3 days
cted on 30,000 cells. Values are plotted as -fold induction relative to
te inductions. Representative data from two independent experiments
eated, and TPA treated). Cells were treated in duplicate to control for
icate to account for variability in the RT and PCRs. To normalize for the
ultiplex) and quantified using a differently labeled probe. Threshhold
acted from corresponding Ct values for the GAPDH and expressed as
esented by dotted lines.ere in
re colle
f triplica
FN-g tr
in dupl
tube (mmedium. For IFA, cells were aliquoted in 0.8-ml volumes
onto 24-well plates and 200 ml of RPMI 1640 medium
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23CYTOKINES AND REACTIVATION OF KSHV LYTIC REPLICATIONwith or without 53 inducing agent: TPA (Calbiochem-
Novabiochem Corp., La Jolla, CA), ionomycin (Sigma
Chemical Co., St. Louis, MO), recombinant IL-2 (Gen-
zyme Diagnostics, Cambridge, MA), and IL-1a, IL-1b,
IL-6, TNF-a, granulocyte-macrophage colony stimulating
factor, bFGF, dexamethasone, IFN-a, or IFN-g (Boeh-
inger Mannheim GmbH, Mannheim, Germany). Each
nduction was performed in quadruplicate. Cells were
arvested at the appropriate time postinduction for IFA.
or FACS, cells were aliquoted in 40-ml volumes to cul-
ure flasks and cultured with or without inducing agent.
ntibodies and IFA
The MAb 19B4 specific for K8.1 was provided by Dr. B.
orghani. For IFA, cells were washed once in PBS and
esuspended in 150 ml of PBS. Then 10 ml of washed
cells was applied to individual wells of a 32-well staining
slide (Erie Scientific, Portsmouth, NH). Cells were al-
lowed to adhere for 20 min, and the remaining liquid was
removed through aspiration. Slides were immediately
fixed in 50% methanol/50% acetone for 10 min at 220°C.
The slides were then removed, air dried, and stored at
270°C or analyzed immediately. Cells in each well were
rehydrated and blocked in 10 ml of 3% BSA–0.05% so-
ium azide (blocking buffer) for 30 min. Blocking buffer
as removed through aspiration, and 10 ml of 19B4 was
applied to each well for 1 h. The slides were then
washed in 13 PBS/4% Tween 20 for 30 min, followed by
one 30-min wash in 13 PBS. Excess PBS was removed
by suction, and 10 ml of FITC-conjugated goat anti-mouse
econdary antibody (ICN Biochemicals, Inc., Costa
FIG. 4. IFN-a inhibits induction of KSHV late gene (K8.1) expression
y ionomycin. BCBL-1 cells were induced with ionomycin (500 nM) 6
FN-a (60, 600, or 6000 U/ml). At 5 days postinduction, cells were
harvested and examined by flow cytometry for K8.1 expressing cells, as
described for Fig. 3A. The data are presented as the mean percentage
of cells positive for K8.1 staining 6 SD of triplicate inductions.esa, CA) was added at a dilution of 1:200. Secondary
ntibody was removed after 30 min, and slides wereashed as above. Slides were treated with Vectashield
Vector Labs., Burlingame, CA), sealed, and stored at 4°C.
low cytometric analysis
The cells (1.25 3 106) were harvested, washed with
PBS, fixed in 4% paraformaldehyde for 20 min, washed
twice in PBS, resuspended in 200 ml of PBS–1% BSA,
nd transferred to V-bottom 96-well plates. Cells were
ncubated with anti-K8.1 antibody (19B4) for 30 min at
°C and washed twice with PBS–1% BSA. Then cells
ere incubated with FITC-conjugated goat anti-mouse
econdary antibody (ICN Biochemicals, Inc.) for 30 min
t 4°C, washed twice with PBS–1% BSA, and resus-
ended in PBS for analysis on a FACS Calibur flow
ytometer (Becton Dickinson, Mountain View, CA). Liv-
ng cells were gated based on forward and side scat-
er parameters.
T-PCR
Quantitative real-time RT-PCR was carried out in du-
licate using Taqman RT and Taqman PCR with Amplitaq
old reagents. RT was carried out using 2.5 mM random
hexamers at 25°C for 10 min, 48°C for 30 min, and 95°C
for 5 min. PCR was carried out using universal cycle
conditions (2 min at 50°C, 10 min at 95°C, and then 40
cycles of 15 s at 95°C and 1 min at 60°C) on an ABI
PRIZM 7000 Sequence Detector. The primers used
were gapdhF, 59-GAAGGTGAAGGTCGGAGTC; gapdhR,
59-GAAGATGGTGATGGGATTTC; gapdhP, VIC-CAAGCT-
TCCCGTTCTCAGCC-TAMRA; orfK8.1s1, 59-AAAGCGTC-
CAGGCCACCACAGA; orfK8.1s4, 59-fam-ATGCCTTAATAT-
CAGCCTTTTCA-tamra; orfK8.1a3, 59-CACCACTATTTCT-
GCCGTTTTC; orf50s1, 59-CACAAAAATGGCGCAAGATGA;
orf50p, 59-6FAM-AGAAGCTTCGGCGGTCCTG-TAMRA; and
orf50a4, 59-TGGTAGAGTTGGGCCTTCAGTT. All primers
span splice junctions and, hence, only amplified RNA. To
prevent contamination, PCRs were assembled in the
segregated space in which neither KSHV virions nor
cloned KSHV DNA was handled. Carryover of the ampli-
fication product was avoided using positive displace-
ment pipettes and UNGglycosylase in the amplification
reaction. To determine the sensitivity of the assay, RNA
derived from BCBL-1 cells was used (data not shown).
Quantitative analysis revealed that the signal for the lytic
orf50 and orf K8.1 messages was on average 50- to
100-fold lower than the signal for spliced-latent mes-
sages in latently infected BCBL-1 cells, consistent with
prior observations that only 1–5% of BCBL-1 cells un-
dergo spontaneous KSHV replication at any given time
(Renne et al., 1996b). The assay was linearly dependent
on input cell number in the range of 1–105 infected
cells/reaction and we were consistently able to detect 1
infected cell in 105 uninfected cells.
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